G protein pathway suppressor 2 pseudogene 2Genealiases: []
Q-omics provides the consensus-scored GPS2P2 profile across patient tissues and cancer cell-line models. GPS2P2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GPS2P2 is differentially expressed in 6, with the highest sampling consensus in LUSC. Additionally, GPS2P2 RNA expression shows 12,150 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight KIRC, LUSC, and DLBC as cancer lineages where GPS2P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPS2P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPS2P2 survival associations across molecular data types. GPS2P2 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPS2P2 RNA expression–survival associations across cancer types. High GPS2P2 expression shows unfavorable associations in KIRC, LGG, UVM and GBM, but favorable associations in UCS and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GPS2P2 RNA expression.
This table summarizes GPS2P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for GPS2P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPS2P2 shows lower tumor expression in COAD and higher tumor expression in LUSC, HNSC, LUAD, KIRP and LIHC. The LUSC box plot shows higher GPS2P2 RNA expression in tumor versus normal tissue (log2 FC = +0.138, t-test p < 0.001).
This table shows molecular features associated with GPS2P2 in patient tissues and cancer cell lines. In patient samples, GPS2P2 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
